Agile Therapeutics Inc. (AGRX)
Agile Therapeutics Statistics
Share Statistics
Agile Therapeutics has 6.9M shares outstanding. The number of shares has increased by 0.7% in one year.
| Shares Outstanding | 6.9M |
| Shares Change (YoY) | 0.7% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 5.14M |
| Failed to Deliver (FTD) Shares | 16 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 11.74K, so 0.17% of the outstanding shares have been sold short.
| Short Interest | 11.74K |
| Short % of Shares Out | 0.17% |
| Short % of Float | 0.17% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.29 and the forward PE ratio is null. Agile Therapeutics's PEG ratio is 0.
| PE Ratio | -0.29 |
| Forward PE | n/a |
| PS Ratio | 0.21 |
| Forward PS | n/a |
| PB Ratio | -0.26 |
| P/FCF Ratio | -0.44 |
| PEG Ratio | 0 |
Enterprise Valuation
Agile Therapeutics has an Enterprise Value (EV) of 3.82M.
| EV / Sales | 0.19 |
| EV / EBITDA | -0.19 |
| EV / EBIT | -0.4 |
| EV / FCF | -0.4 |
Financial Position
The company has a current ratio of 0.46, with a Debt / Equity ratio of -0.1.
| Current Ratio | 0.46 |
| Quick Ratio | 0.33 |
| Debt / Equity | -0.1 |
| Debt / EBITDA | -0.11 |
| Debt / FCF | -0.23 |
| Interest Coverage | -14.01 |
Financial Efficiency
Return on Equity is 88.64% and Return on Invested Capital is 149.43%.
| Return on Equity | 88.64% |
| Return on Assets | -141.05% |
| Return on Invested Capital | 149.43% |
| Revenue Per Employee | $1.03M |
| Profits Per Employee | $-761.32K |
| Employee Count | 19 |
| Asset Turnover | 1.91 |
| Inventory Turnover | 3.28 |
Taxes
| Income Tax | 1.42M |
| Effective Tax Rate | -9.81% |
Stock Price Statistics
The stock price has increased by 277.22% in the last 52 weeks. The beta is 1.58, so Agile Therapeutics's price volatility has been higher than the market average.
| Beta | 1.58 |
| 52-Week Price Change | 277.22% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 1.14 |
| Relative Strength Index (RSI) | 82.85 |
| Average Volume (20 Days) | 143.29K |
Income Statement
In the last 12 months, Agile Therapeutics had revenue of 19.59M and earned -14.46M in profits. Earnings per share was -6.71.
| Revenue | 19.59M |
| Gross Profit | 10.62M |
| Operating Income | -19.88M |
| Net Income | -14.46M |
| EBITDA | -19.88M |
| EBIT | -13.05M |
| Earnings Per Share (EPS) | -6.71 |
Balance Sheet
The company has 2.56M in cash and 2.17M in debt, giving a net cash position of 385K.
| Cash & Cash Equivalents | 2.56M |
| Total Debt | 2.17M |
| Net Cash | 385K |
| Retained Earnings | -423.17M |
| Total Assets | 14.96M |
| Working Capital | -11.79M |
Cash Flow
In the last 12 months, operating cash flow was -9.58M and capital expenditures 0, giving a free cash flow of -9.58M.
| Operating Cash Flow | -9.58M |
| Capital Expenditures | 0 |
| Free Cash Flow | -9.58M |
| FCF Per Share | -4.44 |
Margins
Gross margin is 54.18%, with operating and profit margins of -101.49% and -73.83%.
| Gross Margin | 54.18% |
| Operating Margin | -101.49% |
| Pretax Margin | -73.83% |
| Profit Margin | -73.83% |
| EBITDA Margin | -101.49% |
| EBIT Margin | -101.49% |
| FCF Margin | -48.88% |
Dividends & Yields
AGRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -343.94% |
| FCF Yield | -227.72% |
Analyst Forecast
Currently there are no analyst rating for AGRX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Apr 11, 2023. It was a backward split with a ratio of 1:50.
| Last Split Date | Apr 11, 2023 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -42.12 |
| Piotroski F-Score | 3 |